<DOC>
	<DOC>NCT01015131</DOC>
	<brief_summary>This study correlated changes from baseline in Ki-67, an immunohistochemical marker of cell proliferation, with changes from baseline in tumor uptake of 3'-deoxy-3'[18F]-fluorothymidine (18F-FLT) following the first cycle of treatment with standard of care neo-adjuvant therapy in participants with breast cancer.</brief_summary>
	<brief_title>18F-FLT-PET in Breast Cancer (MK-0000-139)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<criteria>Has newlydiagnosed stage IIB/IIIA/IIIB locally advanced breast cancer Is eligible for preoperative (neoadjuvant) chemotherapy Has a contraindication to magnetic resonance imaging (MRI) Any condition that would limit ability to undergo MRI or PET scans Is a nursing mother Has moderate to endstage renal disease and is not on dialysis or has renal failure on chronic dialysis</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>